Cargando…

Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration

BACKGROUND: Alpha-synuclein is a key protein in the pathogenesis of Parkinson’s disease. Mutations in the parkin gene are the most common cause of early-onset autosomal recessive Parkinson’s disease, probably through a loss-of-function mechanism. However, the molecular mechanism by which loss of par...

Descripción completa

Detalles Bibliográficos
Autores principales: Van Rompuy, Anne-Sophie, Oliveras-Salvá, Marusela, Van der Perren, Anke, Corti, Olga, Van den Haute, Chris, Baekelandt, Veerle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4477319/
https://www.ncbi.nlm.nih.gov/pubmed/26099628
http://dx.doi.org/10.1186/s13024-015-0017-8
_version_ 1782377733388500992
author Van Rompuy, Anne-Sophie
Oliveras-Salvá, Marusela
Van der Perren, Anke
Corti, Olga
Van den Haute, Chris
Baekelandt, Veerle
author_facet Van Rompuy, Anne-Sophie
Oliveras-Salvá, Marusela
Van der Perren, Anke
Corti, Olga
Van den Haute, Chris
Baekelandt, Veerle
author_sort Van Rompuy, Anne-Sophie
collection PubMed
description BACKGROUND: Alpha-synuclein is a key protein in the pathogenesis of Parkinson’s disease. Mutations in the parkin gene are the most common cause of early-onset autosomal recessive Parkinson’s disease, probably through a loss-of-function mechanism. However, the molecular mechanism by which loss of parkin function leads to the development of the disease and the role of alpha-synuclein in parkin-associated Parkinson’s disease is still not elucidated. Conflicting results were reported about the effect of the absence of parkin on alpha-synuclein-mediated neurotoxicity using a transgenic approach. In this study, we investigated the effect of loss of parkin on alpha-synuclein neuropathology and toxicity in adult rodent brain using viral vectors. Therefore, we overexpressed human wild type alpha-synuclein in the substantia nigra of parkin knockout and wild type mice using two different doses of recombinant adeno-associated viral vectors. RESULTS: No difference was observed in nigral dopaminergic cell loss between the parkin knockout mice and wild type mice up to 16 weeks after viral vector injection. However, the level of alpha-synuclein phosphorylated at serine residue 129 in the substantia nigra was significantly increased in the parkin knockout mice compared to the wild type mice while the total expression level of alpha-synuclein was similar in both groups. The increased alpha-synuclein phosphorylation was confirmed in a parkin knockdown cell line. CONCLUSIONS: These findings support a functional relationship between parkin and alpha-synuclein phosphorylation in rodent brain.
format Online
Article
Text
id pubmed-4477319
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44773192015-06-24 Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration Van Rompuy, Anne-Sophie Oliveras-Salvá, Marusela Van der Perren, Anke Corti, Olga Van den Haute, Chris Baekelandt, Veerle Mol Neurodegener Research Article BACKGROUND: Alpha-synuclein is a key protein in the pathogenesis of Parkinson’s disease. Mutations in the parkin gene are the most common cause of early-onset autosomal recessive Parkinson’s disease, probably through a loss-of-function mechanism. However, the molecular mechanism by which loss of parkin function leads to the development of the disease and the role of alpha-synuclein in parkin-associated Parkinson’s disease is still not elucidated. Conflicting results were reported about the effect of the absence of parkin on alpha-synuclein-mediated neurotoxicity using a transgenic approach. In this study, we investigated the effect of loss of parkin on alpha-synuclein neuropathology and toxicity in adult rodent brain using viral vectors. Therefore, we overexpressed human wild type alpha-synuclein in the substantia nigra of parkin knockout and wild type mice using two different doses of recombinant adeno-associated viral vectors. RESULTS: No difference was observed in nigral dopaminergic cell loss between the parkin knockout mice and wild type mice up to 16 weeks after viral vector injection. However, the level of alpha-synuclein phosphorylated at serine residue 129 in the substantia nigra was significantly increased in the parkin knockout mice compared to the wild type mice while the total expression level of alpha-synuclein was similar in both groups. The increased alpha-synuclein phosphorylation was confirmed in a parkin knockdown cell line. CONCLUSIONS: These findings support a functional relationship between parkin and alpha-synuclein phosphorylation in rodent brain. BioMed Central 2015-06-23 /pmc/articles/PMC4477319/ /pubmed/26099628 http://dx.doi.org/10.1186/s13024-015-0017-8 Text en © Rompuy et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Van Rompuy, Anne-Sophie
Oliveras-Salvá, Marusela
Van der Perren, Anke
Corti, Olga
Van den Haute, Chris
Baekelandt, Veerle
Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration
title Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration
title_full Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration
title_fullStr Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration
title_full_unstemmed Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration
title_short Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration
title_sort nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4477319/
https://www.ncbi.nlm.nih.gov/pubmed/26099628
http://dx.doi.org/10.1186/s13024-015-0017-8
work_keys_str_mv AT vanrompuyannesophie nigraloverexpressionofalphasynucleinintheabsenceofparkinenhancesalphasynucleinphosphorylationbutdoesnotmodulatedopaminergicneurodegeneration
AT oliverassalvamarusela nigraloverexpressionofalphasynucleinintheabsenceofparkinenhancesalphasynucleinphosphorylationbutdoesnotmodulatedopaminergicneurodegeneration
AT vanderperrenanke nigraloverexpressionofalphasynucleinintheabsenceofparkinenhancesalphasynucleinphosphorylationbutdoesnotmodulatedopaminergicneurodegeneration
AT cortiolga nigraloverexpressionofalphasynucleinintheabsenceofparkinenhancesalphasynucleinphosphorylationbutdoesnotmodulatedopaminergicneurodegeneration
AT vandenhautechris nigraloverexpressionofalphasynucleinintheabsenceofparkinenhancesalphasynucleinphosphorylationbutdoesnotmodulatedopaminergicneurodegeneration
AT baekelandtveerle nigraloverexpressionofalphasynucleinintheabsenceofparkinenhancesalphasynucleinphosphorylationbutdoesnotmodulatedopaminergicneurodegeneration